Hypercalcemia Associated with Hematologic Malignancies
The estimated annual incidence rate of hypercalcemia of malignancy is about 150 new cases per million population per year (Mundy et al. 1980). It is likely to affect 20%–40% of patients with malignancies during the course of their disease. The incidence of hypercalcemia of malignancy varies between 0.07% in a population-based study of one million inhabitants (Mundy et al. 1980) and 1.1% in a large epidemiological study of hospital in- and outpatients performed at a major cancer hospital (Vassilopoulou-Sellin et al. 1993).
KeywordsMultiple Myeloma Chronic Lymphatic Leukemia PTHrP Gene Parathyroid Hormone Related Protein Osteoclast Activate Factor
Unable to display preview. Download preview PDF.
- Nakamura Y, Bando H, Shintani Y, Yokogoshi Y, Saito S (1992) Serum parathyroid hormone-related protein concentrations in patients with hematologic malignancies or solid tumors. Acta Endocrinol (Copenh) 127:324–330Google Scholar
- Sato K, Fujii Y, Kasono K, Ozawa M, Imamura H, Kanaji Y, Kuroxawa H, Tsushima T, Shizume K (1989) Parathyroid hormone related protein and interleukin 1-alpha synergistically stimulate bone resorption in vitro and increase the serum calcium concentration in vivo. Endocrinology 124:2172–2178PubMedCrossRefGoogle Scholar
- Watanabe T, Yamaguchi K, Takatsuki K, Osame M, Yoshida M (1990) Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type 1 (HTLV-1) carriers and adult T cell leukemia patients that can be transactivated by HTLV-1 tax gene. J Exp Med 172:759–765PubMedCrossRefGoogle Scholar